TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00908232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg orally daily, days 1-14 for cycles 5 to 8
Study: NCT03270566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Domestic ion-exchange water softener
Description: Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
Study: NCT01366287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: 25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: 25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: 25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
Study: NCT01790126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARN-509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARN-509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist
Study: NCT02354313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation.
Study: NCT00455325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: First Intervention (3 weeks)
Description: once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Second Intervention (3 weeks)
Description: Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Study: NCT02379728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Position Sensor
Description: The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-PrenaBelt
Description: The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
Study: NCT00455325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Third Intervention (3 weeks)
Description: Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Fourth Intervention (3 weeks)
Description: Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Study: NCT02435966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Dry needling
Description: Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Standard manual therapy in the upper trapezius or the levator scapulae

Intervention type: OTHER
Group type: OTHER
Intervention: Manual therapy
Description: Standard manual therapy in the upper trapezius or the levator scapulae
Study: NCT00490009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexxar
Description: Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.~Bexxar will be administered to provide the following patient-specific radiotherapy:~* Platelet count of 150,000/mm³ = 75 cGy~* Platelet count ≥ 100,000/mm³ but \< 150,000/mm³ = 65 cGy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Iodide (KI)
Description: Administered to prevent thyroid blockage 130 mg orally 3 times a day,
Study: NCT02159196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylcysteine and salbutamol
Description: routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine
Description: nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
Study: NCT02953366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMS Mometasone gel
Description: The patient should administer 1 spray in each nostril once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone spray nasal
Description: The patient should administer 1 spray in each nostril once daily.
Study: NCT01211197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: BI 10773 / metformin tablet
Description: BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: BI 10773 tablet and metformin tablet
Description: BI 10773 and metformin single tablets, administered together in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: BI 10773 / metformin tablet
Description: BI 10773 / metformin fixed dose combination tablet in fasted state
Study: NCT02702973

Intervention type: OTHER
Intervention: Observe the fundus characteristics after therapy.
Study: NCT02977208

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sparse blood sampling
Description: Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sparse blood sampling
Description: Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urine sampling
Description: Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urine sampling
Description: Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DNA extraction
Description: Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G\>T and SLC22A4 c.1507C\>T polymorphisms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DNA extraction
Description: Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G\>T and SLC22A4 c.1507C\>T polymorphisms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: All patients undergoing chronic treatment with gabapentin are being recruited.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: All patients undergoing chronic treatment with gabapentin are being recruited.
Study: NCT01266135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576
Description: QAX576 10 mg/kg intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QAX576 intravenous infusion
Study: NCT04314141

Intervention type: PROCEDURE
Intervention: Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty
Description: Send a questionnaire to patients to collect informations about:~* Sexual quality of life before and after the surgery~* Satisfaction after surgery~Data collection in medical file :~* Surgery outcomes~* Functional outcomes

Intervention type: PROCEDURE
Intervention: Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty
Description: Send a questionnaire to patients to collect informations about:~* Sexual quality of life before and after the surgery~* Satisfaction after surgery~Data collection in medical file :~* Surgery outcomes~* Functional outcomes
Study: NCT03539783

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory epithelial cell brushing
Description: At specified time points, nasal brushings will be performed to obtain RNA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory epithelial cell brushing
Description: At specified time points, nasal brushings will be performed to obtain RNA.
Study: NCT03776019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVWF device
Description: The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AVWF device
Description: The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.
Study: NCT02326012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Individual Therapy for Adolescents
Study: NCT04322942

Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width
Description: Monocyte Distribution Width as part of the CBC result.

Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width
Description: Monocyte Distribution Width as part of the CBC result.

Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width
Description: Monocyte Distribution Width as part of the CBC result.

Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width
Description: Monocyte Distribution Width as part of the CBC result.
Study: NCT01103635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD40 agonist monoclonal antibody CP-870,893
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02349451

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ABT-122
Study: NCT02301650

Intervention type: DRUG
Intervention: Lamivudine
Description: mothers use Lamivudine in late pregnancy

Intervention type: DRUG
Intervention: Telbivudine
Description: mothers use Telbivudine in late pregnancy

Intervention type: DRUG
Intervention: Tenofovir
Description: mothers use Tenofovir in late pregnancy
Study: NCT02379728

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-PrenaBelt
Description: The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
Study: NCT03782246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT
Description: Mindfulness- based Cognitive Therapy
Study: NCT02673203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring System (CGMS)
Description: The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring System (CGMS)
Description: The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food log
Description: The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food log
Description: The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
Study: NCT01268722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon angioplasty
Description: This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary stenting
Description: This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
Study: NCT02290522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Biopsy of lesion for molecular characterization
Study: NCT03672877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.
Study: NCT04065009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Experimental drug will be administered intraperitoneally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo will be administered intraperitoneally
Study: NCT02711618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Contour I V3
Description: Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
Study: NCT02602054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Standard left thoracotomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: - Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days
Study: NCT03242551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
Study: NCT00779051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem 10mg tablets
Study: NCT02274636

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: A comparison between discs and gel
Study: NCT02045966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail
Description: Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Description: DCV 30 mg + ASV 200 mg + BMS-791325 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study: NCT01009203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
Study: NCT02558192

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus GG
Description: 1 vials q12 for 15 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 1 vials q12 for 15 days
Study: NCT02796001

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human rhinovirus
Description: human rhinovirus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human rhinovirus
Description: human rhinovirus

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: 4 volunteers were not re-challenged and did not participate in the second challenge